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We spoligotyped and screened 1490 clinical Mycobacterium tuberculosis complex strains from Northern
and Greater Accra regions of Ghana against INH and RIF using the microplate alamar blue phenotypic
assay. Speciﬁc drug resistance associated genetic elements of drug resistant strains were analyzed for
mutations. A total of 111 (7.5%), 10 (0.7%) and 40 (2.6%) were mono-resistant to INH, RIF, and MDR,
respectively. We found the Ghana spoligotype to be associated with drug resistance (INH: 22.1%;
p ¼ 0.0000, RIF: 6.2%; p ¼ 0.0103, MDR: 4.6%; p ¼ 0.0240) as compared to the Cameroon spoligotype
(INH: 6.7%, RIF: 2.4%, MDR: 1.6%). The propensity for an isolate to harbour katG S315T mutation was
higher in M. tuberculosis (75.8%) than Mycobacterium africanum (51.7%) (p ¼ 0.0000) whereas the
opposite was true for inhApro mutations; MAF (48.3%) compared to MTBSS (26.7%) (p ¼ 0.0419). We
identiﬁed possible novel compensatory INH resistance mutations in inhA (G204D) and ahpCpro (-88G/A
and -142G/A) and a novel ndh mutation K32R. We detected two possible rpoC mutations (G332R and
V483G), which occurred independently with rpoB S450L, respectively. The study provides the ﬁrst evi-
dence that associate the Ghana spoligotype with DR-TB and calls for further genome analyses for proper
classiﬁcation of this spoligotype and to explore for ﬁtness implications and mechanisms underlying this
observation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tuberculosis (TB) remains an important global health problem,
with close to 9 million new cases per year and a pool of approxi-
mately 2 billion latently infected individuals worldwide [1]. Of
particular concern are the on-going epidemics of drug resistant TB
(DR-TB), which threaten to make TB incurable. The main causativeh (D. Yeboah-Manu).
r Ltd. This is an open access articleagents for human tuberculosis are Mycobacterium tuberculosis
sensu stricto (MTBSS) and Mycobacterium africanum (MAF), both
members of the M. tuberculosis complex (MTBC). Of particular in-
terest toWest Africa is MAF, which causes up to 50% of human TB in
some countries [2].
Drug resistance to isoniazid (INH) and rifampicin (RIF), the two
backbone-drugs of the directly observed treatment short-course
(DOTS) regimen, can negatively affect the successful outcome of
treatment of TB [3,4]. The pro-drug INH requires activation by
catalase peroxidase encoded by the katG of the target bacterium.
Activated INH disturbs cell wall synthesis by binding to a 2-trans-under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mycolic acid synthesis [5]. Rifampicin kills bacteria by halting the
elongation of a nascent polynucleotide by occluding the path of the
growing RNA through the polymerase [6]. katG (mostly S315T) and
inhApro (mostly -15C/T) mutations are associated with high and
low level INH resistance respectively [7]. Even though the katG
mutation (inactive INH) and inhApro substitutions (overproduction
of inhA) are the major causes of INH resistance, other loci such as
ndh, inhA and ahpCpro have either been implicated with drug
resistance or restoring the ﬁtness cost associated with some high
level resistance mutations [8,9]. Some rpoB mutations alter the 3D
structure of the rpoB hence affecting the conformation of the RIF-
binding pocket which in effect prevents the rigid structure of RIF
from binding to the bacterial polymerase to inhibit transcription
[6,10]. Even though rpoBmutations account for most RIF resistance
in TB, mutations within the rpoA and rpoC have also been impli-
cated with restoring the ﬁtness cost associated with the acquisition
of rpoB mutations [11]. Both katG S315T and rpoB S450L mutations
(the most dominant INH and RIF resistance associated mutations
respectively) have been associated with no/low ﬁtness cost which
may explain their dominance in clinical MTBC strains even though
they confer high-level resistance [12,13].
Though non-compliance of therapeutic regimen may contribute
to the development of DR-TB, the contribution of the infecting
bacteria cannot be underestimated. The Beijing strain of lineage 2 is
associated with hyper-virulence and drug resistance even though
reports on drug resistance are sometimes conﬂicting [14]. On the
other hand, Lineage 1 is reported to be less virulent and negatively
associated with high cost mutations, which are mostly responsible
for high-level drug resistance [13e15]. This indicates that different
genotypes of the MTBC may be associated with resistance to spe-
ciﬁc drugs and these associations may be driven by speciﬁc genetic
alterations.
In this study, we screened MTBC strains isolated from pulmo-
nary TB patients reporting to selected health centres from the
Northern and Greater Accra Regions of Ghana for drug resistance to
INH and RIF. We analysed speciﬁc genetic elements for DR associ-
ated mutations by DNA sequencing of implicated genes and looked
for associations among drug resistance, bacterial genotypes and
origin of the isolates.2. Methodology
2.1. Ethical statement and participant enrolment
The Institutional Review Board of the Noguchi Memorial Insti-
tute for Medical Research (NMIMR) approved the study and its
protocols. Following informed consent, consecutive sputum smear-
positive TB cases whowere not already taken anti-TB drugs or have
been put on therapy for notmore than 2weeks were recruited from
all TB diagnostic centres in the Accra Metropolitan (Southern Re-
gion) and the Mamprusi East (Northern Region) Health Adminis-
trations (Figure 1) from August 2012 to September, 2014. The
standard procedure for sputum sample collection as outlined by the
National Tuberculosis Control Program (NTP) for routine diagnosis
of TB in Ghana was followed. Informed written consent was sought
from all participants unless the participant was illiterate; in which
case witnessed oral consent was used. Consent was sought from
guardians of children below the age of 18 before enrolment into the
study and in some cases child assent was also sought. Data
collected from enrolled patients included age, sex, bacterial burden
on day of diagnosis and TB treatment history.2.2. Mycobacterial isolates
The sputum samples were decontaminated with 5% oxalic acid
[16], and inoculated on Lowenstein-Jensen Media (supplemented
with either glycerol or pyruvate) slants, incubated at 37 C until
growth was observed. Colonies from positive cultures were sub-
cultured on similar media and incubated as above until conﬂuent
growth was observed. The isolates (1490) were conﬁrmed MTBC by
PCR ampliﬁcation of IS6110, genotyped as MTBSS, MAF and/or
Mycobacterium bovis by large sequence polymorphism (LSPs)
detecting region of difference (RD) 4, 9 and 12 [17] and spoligo-
typing as described by Kamerbeek et al. [18].
2.3. Anti-TB drug susceptibility testing
Micro-plate alamar blue assay (MABA) for drug susceptibility
testing (DST) was performed in clear-bottomed, 96-well micro-
plates (Nunc International, Rochester, NY, US). Drugs stocks were
prepared by following standard protocols [19], and MABA-DST set
up by following a modiﬁcation of the method described by Franz-
blau et al. [20].
In summary, mycobacterial inoculum was prepared by emulsi-
fying a loop full of logarithmic growing mycobacteria in sterile
Middlebrook 7H9 [Difco, Detroit, Michigan] broth supplemented
with 0.2% glycerol [Sigma-Aldrich, Steinheim, Germany] and
0.001% casitone [Difco] (7H9-GC) and adjusted spectrophotomet-
rically to OD600¼ 1.0 containing approximately 1 108 cfu/mL. This
suspension was diluted 1:25 with 7H9-GC for inoculation. All
perimeter wells of the plate were ﬁlled with 200 uL of sterile water
to prevent evaporation of the content of inner wells. The test wells
consisted of 7H9-GC/Tween 80 [Sigma-Aldrich] medium and
respective concentration of testing drugs, (which were serially
diluted to ﬁnal concentrations of 0.03125e1.0 ug/mL and 0.0625 to
2.0 ug/mL for INH and RIF respectively) before inoculation with
100 mL of the mycobacterial suspension containing approximately
4  106 cfu/mL. The plates were incubated at 37 C for 7 days, and
bacterial viability was tested with freshly prepared 1:1 v/v of ala-
mar blue reagent [Trek Diagnostic Systems, OH, USA] and 10%
Tween 80. The minimum inhibitory concentration (MIC) deﬁned as
the concentration of drug in the ﬁrst blue well for each drug, was
then recorded (S1). The critical drug concentration was 0.25 ug/
mL for both drugs [20]. The positive and negative controls for each
set were drug-free media inoculated with bacterial suspension and
un-inoculated containing media only respectively.
2.4. Isolation of genomic DNA
The protocol used for the extraction of genomic DNA was a
synthesis of the protocols of Van Soolingen et al. [21] and K€aser
et al. [22]. Brieﬂy, the mycobacterial cell wall was disrupted by
adding lysozyme (50 mL lysozyme of 10 mg/mL) vortexed and
incubated overnight, followed by addition of 75 mL of 10% SDS,10 mL
proteinase K (20 mg/mL), vortexed softly and incubated 15 min at
65 C. After, the incubation, 100 mL of 5 M NaCl was added, followed
by 100 mL CTAB which was pre-warmed at 65 C. After vortexing,
the extracted DNA was puriﬁed by chloroform/isoamyl alcohol
extraction. The DNA contained in the upper phase was precipitated
with isopropanol and washed with ethanol. The dried DNA was
then re-suspended in 100 uL Tris EDTA buffer and stored at 4 C
until use.
2.5. PCR ampliﬁcation and DNA sequencing of genetic elements
Drug resistant isolates were used for targeted sequencing ana-
lyses. Eight drug resistance associated genetic elements (rpoB, rpoA
Figure 1. Map of Ghana showing the selected health centers from the two regions used for the study.
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for INH resistant strains) were analysed for mutations.
All PCR reactions were set up as previously described [23]. In
summary, each set up contained 3 mL of 10X buffer, 1.8 mL of 15 mM
MgCl2, 3 mL of Q solution, 0.6 mL of 10 mM dNTP mix, 1.8 mL of each
primer, 0.2 mL of Hot-start Taq polymerase from Qiagen, 14.8 mL of
nuclease-free water and 3 mL of template DNA. Cycling conditions
were: initial denaturation at 95 C for 15 min and 35 cycles of
denaturation at 96 C for 1 min, annealing at speciﬁc Tm (Table 1)for 1 min, extension at 68 C for 1 min and ﬁnal extension at 72 C
for 10 min. The obtained amplicons were shotgun sequenced in
both directions by outsourcing to Macrogen Europe.
2.6. Data analyses
The DNA sequences were screened for possible mutations by
comparing with the standard strain; H37Rv genome downloaded
from the tuberculist database [24] using the Staden software [25].
Table 1
Primers and conditions for PCR ampliﬁcation of genetic element.
No. Name Sequence (50e30) Tm (C) Target Product size
1 rpoA1F GCATTCCAGTCGATTCCATC 57 rpoA 560 bp
2 rpoA1R CCAAGATCGCCTTCTGATGT
3 rpoA2F GGACGTCGAAAGGAAGAAGA 57 rpoA 542 bp
4 rpoA2R GTCTCCACGTCCAGGATCAG
5 rpoBF GTAGTCCACGCCGTAAACGG 65 rpoB 601 bp
6 rpoBR ACGTCCATGTAGTCCACCTCAG
7 rpoCF CGAAAACCTCTACCGCGAAC 64 rpoC 650 bp
8 rpoCR GCGACAGGATGTTGTTGGAG
9 inhAproF ATCACCACCGCCGCTGAAGC 65 inhApro 650 bp
12 inhAproR GTTCGGGTACCCGGGAATG
11 inhA1F CTACATCGACACCGATATGAC 57 inhA 600 bp
12 inhA1R GACCGTCATCCAGTTGTAG
13 inhA2F GCATCAACCCGTTCTTCGAC 57 inhA 550 bp
14 inhA2R TAATGCCATTGATCGGTGATAC
15 ahpCproF ACCACTGCTTTGCCGCCACC 70 ahpCpro 340 bp
16 ahpCproR CCGATGAGAGCGGTGAGCTG
17 katGF CCAGCGGCCCAAGGTATC 65 katG 820 bp
18 katGR GCTGTGGCCGGTCAAGAAGAAGT
19 ndhF ATCACCACCGCCGCTGAAGC 64 ndh 589 bp
20 ndhR GTTCGGGTACCCGGGAATG
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tion(s) for veriﬁcation. We compared the proportion and kind of
mutations inMTBSS andMAF as well as the geographic origin of the
isolates. The level of resistance between the different genotypes
and the kind of mutation were compared with ﬁshers exact tests
using stata statistical package [26], with signiﬁcance threshold set
to P < 0.05.
3. Results
3.1. Clinical data of drug-resistant patients
Among the 161/1490 (10.8%) patients fromwhom MTBC strains
resistant to at least one drug were isolated, 114 (70.8%) and 47
(29.2%) were males and females respectively. Drug-resistant TB
patients up to 50 years were 113 (70.2%) whereas those above 50
years were 48 (29.8%). Whereas 128 (79.5%) of the DR-TB patients
were having TB for the ﬁrst time, 33 (20.5%) had been treated for TB
before the current episode. Bacterial burden of the DR-TB patients
stood at 9 (5.6%) scanty, 83 (51.6%) 1þ, 29 (18.0%) 2þ and 40 (24.8%)
3þ. 12.8% of drug resistant TB patients as compared to 12.2% of drug
susceptible TB patients were HIV positive. Whereas 140 (87.0%) of
the DR-TB patients were from the South representing 10.4% of TB
patients reporting to the selected hospitals in the region, 21 (13.0%)
were from the North representing 15.0% of the patients reporting to
the selected hospital from that region.
3.2. Drug-susceptibility rates
One thousand four hundred and ninety isolates (MTBSS: 1208;
81.1%, MAF: 272; 18.3% and M. bovis: 10; 0.7%) were tested and of
these, 111 (7.5%), 10 (0.7%), 40 (2.6%) and 161 (10.8%) were INHTable 2
Distribution of drug resistance among 1490 MTBC isolates from two distant regions
of Ghana.
Resistance Total
(1490)
Accra Metro
(1350)
Mamprusi
East (140)
p-value
INHr 111; 7.45% 99; 7.33% 12; 8.60% 0.6108
RIFr 10; 0.67% 8; 0.59% 2; 1.40% 0.2404
MDR 40; 2.64% 33; 2.44% 7; 5.00% 0.0924
ANY 161; 10.80% 140; 10.37% 21; 15.00% 0.0850mono-resistant (INHr), RIF mono-resistant (RIFr), multi-drug
resistant (MDR) and resistant to at least one drug (ANYr) respec-
tively. Comparing these results to a previous report from Ghana
[27], indicates that the level of drug resistance has remained fairly
low over the past 8 years (OR ¼ 1.11, 95% CI ¼ 0.79e1.52,
p ¼ 0.5186). There was no statistical association of speciﬁc DR-TB
with the two regions understudied (Table 2). We found 90/1208
(7.5%), 19/272 (7.0%) and 2/10 (20%) of the MTBSS, MAF andM. bovis
respectively were INHr. None of the MAF isolates were RIFr, how-
ever, there were 9 (0.7%) MTBSS and 1 (10.0%) M. bovis resistant to
only RIF. On the other hand, the MDR strains were 10 (3.7%) MAF
and 30 (2.5%) MTBSS. There was no difference between the DR rates
of MAF and MTBSS (Table 3). When the strains were further strat-
iﬁed into spoligotypes, the DR rates as summarized in Table 4
indicate a high proportion of DR among the Ghana spoligotype of
Lineage 4. For example, there were 7.4% of Cameroon spoligotype as
compared to 23.6% of the Ghana spoligotype with resistance to at
least one drug (OR ¼ 0.26; CI 0.17e0.41; p ¼ 0.0000).
3.3. Drug resistance conferring mutations
Mutations were found in all targets analysed but rpoA of RIF
resistant isolates (Table 5) with the katG S315T (70.9%) and rpoB
S450L (52.0%) as the dominant INH and RIF resistance-associated
mutations respectively followed by inhApro -15C/T (15.9%) and
rpoB D435V (22.0%). As shown (Table 6), 91 (75.8%) of INH resistant
MTBSS compared to 15 (51.7%) MAF harboured katGmutations (OR:
3.73, 95% CI: 1.56e9.09, p¼ 0.0013). In contrast, within the inhApro,
32 (26.7%) MTBSS as compared to 14 (48.3%) INH resistant MAF
harboured mutations (OR: 0.39, 95% CI: 0.16e0.98, p ¼ 0.0419).
Analysis of other targets associated with INH resistance, found the
proportion of INH resistantMAFwith ndh (5; 17.2%)mutations to be
higher than MTBSS (1; 0.8%) (OR: 0.04, 95% CI: 0.00e0.39,Table 3
Distribution of drug resistance by the human adapted MTBC.
Drug Total
(1480)
MTBSS
(1208)
MAF
(272)
p-value 95% CI
INHr 109; 7.4% 90; 7.5% 19; 6.9% 0.8979 0.63e1.89
RIFr 9; 0.6% 9; 0.7% 0; 0.0% 0.3794 0.44eInf
MDR 40; 2.7% 30; 2.5% 10; 3.7% 0.2988 0.31e1.55
ANYr 158; 10.7% 129; 10.7% 29; 10.7% 0.9999 0.65e1.59
Table 4
Comparing the proportion of drug resistant Ghana spoligotype of MTBSS to other
prominent spoligotypes in the Ghana.
Resistance Cameroon
(806)
Ghana
(195)
OR 95% CI p-value
INH 54 (6.7%) 43 (22.1%)* 0.25 0.16e0.40 0.0000
RIF 19 (2.4%) 12 (6.2%)* 0.37 0.17e0.85 0.0103
MDR 13 (1.6%) 9 (4.6%)* 0.34 0.13e0.91 0.0240
ANY 60 (7.4%) 46 (23.6%)* 0.26 0.17e0.41 0.0000
MAF WA 1 (165) Ghana (195)
INH 25 (15.2%) 43 (22.1%) 0.63 0.35e1.12 0.1059
RIF 10 (6.1%) 12 (6.2%) 0.98 0.37e2.56 0.9998
MDR 10 (6.1%) 9 (4.6%) 1.33 0.47e3.81 0.6384
ANY 25 (15.2%) 46 (23.6%)* 0.58 0.32e1.02 0.0472
MAF WA 2 (107) Ghana (195)
INH 6 (5.6%) 43 (22.1%)* 0.21 0.07e0.52 0.0001
RIF 1 (0.9%) 12 (6.2%)* 0.144 0.00e1.00 0.0372
MDR 1 (0.9%) 9 (4.6%) 0.19 0.00e1.45 0.1040
ANY 6 (5.6%) 46 (23.6%)* 0.19 0.06e0.48 0.0000
MAF WA 1: M. africanum West Africa 1 (Lineage 5).
MAF WA 2: M. africanum West Africa 2 (Lineage 6).
* Signiﬁcantly higher.
Table 6
Distribution of mutations by human adapted MTBC species.
Target MTBSS MAF OR 95% CI p-value
katG 91; 75.8%* 15; 51.7% 3.73 1.56e9.09 0.0013
inhApro 32; 26.7% 14; 48.3%* 0.39 0.16e0.98 0.0419
inhA 17; 14.2% 1; 3.5% 4.59 0.66e199.77 0.1999
ahpCpro 2; 1.7% 1; 3.5% 0.48 0.02e28.99 0.4802
ndh 1; 0.8% 5; 17.2%* 0.04 0.00e0.39 0.0011
rpoB 38; 97.4% 8; 80.0% 8.88 0.42e572.05 0.1018
rpoC 5; 12.8% 0; 0.0% Inf 0.22-Inf 0.5834
* Signiﬁcantly higher.
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were, 17 (14.2%) and 2 (1.7%) in MTBSS as compared to 1 (3.5%) and
1 (3.5%) MAF (p ¼ 0.1999 and p ¼ 0.4802 respectively), All the 16
isolates with the novel inhAmutation (G204D)wereMTBSS Lineage
4 spoligotypes (11 Ghana, 3 Cameroon, 1 Uganda I and 1 LAM).
MTBSS strains with rpoBmutations were 38 (97.4%) as compared to
8 (80.0%) MAF (p ¼ 0.1018) as shown in Table 6. The only RIF
resistant bovine strain had two rpoB mutations Q432P and I491S
(Table 5; S1).Table 5
Identiﬁed mutations from drug resistant MTBC.
Gene (No. of isolates) DNA mutation Isolates with
speciﬁc SNP
inhApro (151) -8T/C 5 (3.3%)
15C/T 24 (15.9%)
17G/C 1 (0.7%)
102G/A 16 (10.6%)
47G/C 1 (0.7%)
katG (151) G944C 107 (70.9%)
inhA (151) G611A* 16 (10.6%)
T233C 1 (0.7%)
ahpCpro (151) 54C/T 1 (0.7%)
88G/A* 2 (1.3%)
142G/A* 1 (0.7%)
ndh (151) G349A 4 (2.6%)
C411T 1 (0.7%)
A95G & G349A 1 (0.7%)
rpoB (50) A1295C 1 (2.0%)
A1295C & T1472G 1 (2.0%)
C1294A 1 (2.0%)
A1304T 11 (22.0%)
G1303T 1 (2.0%)
C1332T 1 (2.0%)
A1334G 2 (4.0%)
CA1333/4TG 2 (4.0%)
C1333G 2 (4.0%)
C1333T 1 (2.0%)
C1349T 26 (52.0%)
rpoC (50) G994C 2 (4.0%)
T1448G 3 (6.0%)
The 50 RIF resistant strains include the 49 RIF mono-resistant and/or MDRMTBSS and MA
Resistant strains include the 109 INH mono-resistant and 40 MDR MTBSS and MAF in 2
* Novel Mutation.
y Previously described in RIF resistant E. coli.Exploring themutations in the genetic elements under study for
association among the Lineage 4 spoligotypes (Table 7) found 25.6%
of the Ghana spoligotype to harbour inhAmutations as compared to
7.4% of the Cameroon spoligotype (OR ¼ 4.23, 95% CI ¼ 1.13e19.82,
p ¼ 0.0220). In addition, all the 3 strains with the novel ndh mu-
tation (V117I) belonged to MAF West Africa 2. The 2 strains with
rpoC G332R were Cameroon spoligotypes whereas the 3 strains
with rpoC V483G were Ghana spoligotype but were all carrying
rpoB S450L.4. Discussion
The objectives of this study were 1) to determine the drug (INH
and RIF) susceptibility proﬁle of MTBC strains, 2) to probe the ge-
nomes of DR isolates for mutations and 3) to compare the identiﬁed
mutations between species. The main ﬁndings from this prospec-
tive study show that 1) the rate of INHr, RIFr and MDR TB has
remained fairly constant over the years with relatively highAmino acid
change
Other
mutations
e 5: katG S315T, 2: ndh V117I
8: inhApro -102G/A
e
e 8: katG S315T, 8: inhApro -15C/T
katG S315T
S315T 16: inhA G204D, 8:
inhApro -102G/A: 5: inhApro -8T/C,
1: inhApro -47G/C, 2: ndh V117I, 2:
ahpCpro -88G/A, 1: ahpCpro -142 G/A
G204D* 16: katG S315T
V78A ndh: K32R; aphCpro: -54C/T
e ndh: K32R; inhA: V78A
e 2: katG; S315T
e katG: S315T
V117I* inhApro; -8T/C katG; S315T
G137G katG; S315T
K32R* & V117I* ahpCpro: -54C/T, inhA: V78A
Q432P
Q432P & I491Sy
Q432K
D435V
D435Y
S441L
H445R
H445C
H445D
H445Y
S450L 2: rpoC G332R, 3: rpoC V483G
G332R rpoB; S450L
V483G rpoB; S450L
F strains in addition to the single RIF mono-resistantM. bovis. Similarly, the 151 INH
INH mono-resistant M. bovis.
Table 7
Comparing mutation sites among Lineage 4 Spoligotypes.
Cameroon (54) Ghana (43) OR 95% CI p-value
katG 39; 72.2% 32; 74.4% 0.89 0.32e2.42 0.9998
inhApro 14; 25.9% 9; 20.9% 1.32 0.46e3.92 0.6357
inhA 4; 7.4% 11; 25.6%* 0.24 0.05e0.88 0.0220
* Signiﬁcantly higher.
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Lineage 4 is associated with drug resistance 3) that INH resistant
MTBSS are more likely to harbour katG mutations as compared to
INH resistant MAF which preferred inhApro mutations, and 4) that
RIF resistant Cameroon and Ghana spoligotypes of Lineage 4 may
harbour different compensatory rpoC mutations even though they
share the same drug resistant rpoB mutation.
The proportion of INHr, RIFr and MDR among the close to 1500
isolates analysed were 7.5%, 0.7% and 2.6% respectively which was
found not to be signiﬁcantly different from two previous reports
[23,27]. This indicates that the rate of MDR and RIF mono resistant
TB in the country has remained fairly constant and low over the
years indicating some success for the National control programme.
However, the 111 (7.5%) INH mono-resistance as compared to 10
(0.7%) RIF mono-resistance suggests that emergence of INH resis-
tance predates RIF resistance towards generation of MDR-TB. This
ﬁnding has important implications if GeneXpert is used as a sur-
rogate for detection of MDR-TB as most INH-mono-resistant cases
would be treated as susceptible with ﬁrst-line regimen that con-
tains INH and could render the ﬁrst-line regimen ineffective.
Stratifying the isolates by geographical region shows that the
northern part of the country has higher proportion of MDR-TB
compared to the south and the national average of approximately
2% according to the national tuberculosis control program (per-
sonal communication with the director). This result calls for
intensifying control activities in Northern Ghana and probably
other rural communities as most of the Global fund activities are
centred in the urban areas especially the Accra Metro Health
Directorate. However, consistent with an earlier study [23], there
was no difference between the proportion of MTBSS and MAF that
were drug resistant (Table 2). This result however, seems to
contradict a study in Ghana that found MTBSS to be more associ-
ated with drug resistance as compared to MAF [28]. However,
resistance to streptomycin (which was not included in the current
study) drove the association found in that study. The Ghana spo-
ligotype of MTBSS Lineage 4, which is the second most dominant
Lineage 4 spoligotype in Ghana [23,28], was found to be associated
with drug resistance whether compared to the most dominant
Cameroon spoligotype or the two lineages of MAF (Table 3). This is
the ﬁrst report that associates the Ghana spoligotype with drug
resistance in any of theWest African countries where this genotype
is prevalent. This association is similar to the association of the
Beijing genotype of Lineage 2 in some geographical settings
[28e32]. However, whereas the Beijing genotype is deﬁned by
other genotyping tools in addition to spoligotyping, the Ghana
spoligotype is merely deﬁned by spoligotyping, which calls for
further genomics studies for proper classiﬁcation. Drug resistance
mutations in most bacteria, including MTBC is often associated
with a ﬁtness cost, and therefore the ability of a strain to develop
and transmit effectively is inﬂuenced by the genetic background
thatmitigate against the cost. For instance, the Beijing genotype has
been associated with increased virulence and compensatory mu-
tations [32e36]. Drawing from the Beijing experience, it may be
appropriate to infer that the Ghana spoligotype has developed the
capacity to develop drug resistance through some as-yet-
unidentiﬁed evolutionary compensatory mechanism. As high rateof drug resistance is somehow linked with virulence [32e35],
detailed comparative genomics and phenotypic investigations
involving the Ghana spoligotype would highlight the probable
evolutionary forces driving this association with drug resistance.
This ﬁnding partly explains, the higher level of DR-TB observed in
the Northern region of Ghana probably confounded by the domi-
nance of the Ghana spoligotype which is found in higher pro-
portions in that part of the country as compared to the South
[Yeboah-Manu et al., manuscript submitted]. This observation
could also be due to a local transmission of resistant Ghana spoli-
gotype strains instead of emergence of resistance among patients
under therapy similar to an earlier report by Eldholm et al. [37].
This however, would requirewhole genome sequencing of the drug
resistant strains for clarity.
The ﬁnding that INH resistant MTBSS clinical strains have higher
preference for katG mutations as compared to INH resistant MAF
strains which preferred inhApro mutations compares with an
earlier report of a similar study carried out in Ghana [27], and
suggests possible preference for lineage-speciﬁc drug-resistance
mutations. However, whereas that study hypothesized that inhApro
mutation -102G/A which has not been associated with drug resis-
tance was likely to be MAF species-speciﬁc SNP, the mutation was
later detected in some INH resistant MTBSS strains harbouring
either katG S315T or inhApro -15C/T and hence challenged the MAF
species-speciﬁcity of this SNP [23]. In this current study, the mu-
tation was again found in both species (S1), thus conﬁrming the
earlier hypothesis that the mutation could not be species-speciﬁc.
We however hypothesize that the -102G/A, together with -47G/C
and -8T/C SNPs which were also detected in the previous studies
are more likely to be compensatory mutations instead of speciﬁc
phylogenetic markers. This hypothesis is supported by the fact that
the 3 SNPs mentioned above were found concurrently with either
katG S315Tor inhApro -15C/T in INH resistant strains or alone in INH
susceptible strains andwere not species-speciﬁc (S1). Nevertheless,
this hypothesis requires further work for conﬁrmation or other-
wise. However, if this hypothesis is proven to be true, it would have
negative impact on theWHO approvedMTBDRplus line probe assay
which has the inhApro -8T/C SNP as one of the markers for INH
resistance. We also report of a less prevalent inhApro mutation
-17G/C which was earlier reported in some Ghanaian isolates [27],
however unlike the earlier report, this study found the affected
isolate had no other mutation in all the other targets analysed
suggesting that it could be responsible for the observed resistance.
In addition, there was a novel inhA mutation (G204D) which
may be a compensatory mutation for the acquisition of katG S315T
mutations inMTBSSwhereas another novel mutation in ndh (K32R)
could be a drug resistance mutation (Table 4). These conclusions
were drawn from the observation that all the 16 INH resistant
isolates with the inhA G204D mutation also had the katG S315T
mutationwhereas the only isolate with the ndh K32Rmutation had
no other mutation in all the targets analysed apart from another
novel mutation V117I in the same gene. The additional ndh muta-
tion V117I may be a compensatory mutation because it was also
detected in four additional INH resistant strains with katG S315T.
However, whereas all the 3 isolates with the ndh V117I mutation
were MAF Lineage 6, the inhA G204D was detected in 16 MTBSS
Lineage 4 strains of four different spoligotypes with katG S315T
hence ruling out the possibility of a phylogenetic marker (S1). Even
though this novel mutationwas found in four genotypes of Lineage
4, it was found to bemore associated with the Ghana spoligotype as
compared to the Cameroon (OR ¼ 0.24, 95% CI ¼ 0.05e0.88,
p ¼ 0.0220). If this mutation is veriﬁed as compensatory, the as-
sociation with the Ghana spoligotype may explain the positive se-
lection and ﬁxation of INH resistance mutations in the Ghana
spoligotype, similar to the situation with the Beijing genotype [32].
I.D. Otchere et al. / Tuberculosis 99 (2016) 147e154 153The differences in rpoC mutation between RIF resistant
Cameroon and Ghana spoligotypes of Lineage 4 is in line with
earlier work [37], which suggested that under similar physiological
conditions, the genetic background of a particular strain may select
for speciﬁc mutations. However, the physical environment of the
strains may be the driving force for selection and ﬁxation of these
mutations irrespective of the genetic background [38]. Interest-
ingly, these reports are all based on in vitro generated mutant
strains suggesting that, under clinical conditions, the two proposals
may apply. Even though the rpoC mutations G332R and V483G
were found only in Ghana and Cameroon spoligotypes respectively,
they were not spoligotype-speciﬁc (S1), thus ruling out the possi-
bility of them being phylogenetic markers. In addition, the V483G
mutation has been shown to occur at the interface between the
rpoB, rpoA and rpoC of the bacterial polymerase, hence predicted
with high conﬁdence to be a compensatory mutation [11]. This
current work also reafﬁrms the dominance of the rpoB S450L mu-
tations among clinical RIF resistant strains and emphasizes the
possible role played by compensatory mutations for the ﬁxation of
this high level RIF resistance associated mutation among clinical
isolates [11].
The major limitation of this paper rests on the classiﬁcation of
the Ghana genotype of Lineage 4 by spoligotyping alone. However,
the slow generation time and no/low recombination of M. tuber-
culosis complex strains suggest this observation may even hold
with whole genome sequence data. In addition, the number of
isolates from the north was relatively small. Furthermore, all the
genomic regions analyzed were within the previously described
hotspots [39] of the distinct targets analyzed and did not probe new
regions. Nevertheless, the information reported here is useful for
efﬁcient management of TB in Ghana in that it provides conﬁdence
in newly diagnostic tools such as GeneXpert to support detection of
RIF resistance. It also calls for more intensive control activities in
the rural areas as we found more resistant cases in the rural district
in northern Ghana compared to the urban Accra Metro. The ﬁnd-
ings also reafﬁrm the importance of understanding the genomic
diversity of the MTBC in the ﬁght against drug resistant TB.5. Conclusion
This study reports an association between speciﬁc MTBC spoli-
gotype and drug resistance in a geographical certain with most of
the MTBC species circulating in appreciable proportions. The study
provides the ﬁrst evidence that implicate the Ghana spoligotype as
the driver of DR-TB in Ghana and calls for further genome analyses
to best characterize this spoligotype, explore for ﬁtness and
mechanisms underlying this observation. This work also reports
that even though two different genotypes may have the same drug
resistant mutation, they may harbour different compensatory
mutations suggesting sub-lineage speciﬁc epistatic interaction be-
tween drug resistance conferring and non-drug resistant confer-
ring mutations. The study ﬁnally conﬁrms an earlier report that
associatedM. tuberculosis sensu stricto with katG and M. africanum
with inhApro for high-level and low level INH resistance
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